ASTRAZENECA AND BRISTOL-MYERS SQUIBB ANNOUNCE EXPANSION OF WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALISE DAPAGLIFLOZIN IN JAPAN

ASTRAZENECA AND BRISTOL-MYERS SQUIBB ANNOUNCE EXPANSION OF WORLDWIDE
COLLABORATION TO DEVELOP AND COMMERCIALISE DAPAGLIFLOZIN IN JAPAN

AstraZeneca and Bristol-Myers Squibb today announced expansion of their
worldwide collaboration to include the development and commercialisation of
dapagliflozin in Japan.  Dapagliflozin, one of two investigational drugs under
joint development by the companies, is currently being studied in Phase III
clinical trials in several countries, including the U.S., to assess its efficacy
and safety as a once-daily treatment for type 2 diabetes.

In January 2007, AstraZeneca and Bristol-Myers Squibb entered into a global
collaboration, excluding Japan, to enable the companies to research, develop and
commercialise dapagliflozin. The companies now have agreed to co-develop
dapagliflozin in Japan with AstraZeneca having operational and cost
responsibility for all development and regulatory activities on behalf of the
collaboration.  The two companies will jointly market the product in Japan,
sharing all commercialisation expenses and activities and splitting
profits/losses equally. Bristol-Myers Squibb will manufacture dapagliflozin and
also book sales. Dapagliflozin is currently being studied in Phase II clinical
trials in Japan.

“Bristol-Myers Squibb and AstraZeneca have been working together to develop
dapagliflozin for type 2 diabetes for nearly two years - this inclusion of Japan
was a natural progression of our collaboration and an important strategic step
in our relationship,” said Lamberto Andreotti, Executive Vice President and
Chief Operating Officer, Bristol-Myers Squibb. “Our companies have a shared
vision for these diabetes treatments, and this agreement will help ensure we can
successfully launch and maximize the potential of dapagliflozin for the more
than 6 million people in Japan living with type 2 diabetes.”


“Last year, the cost of treating and preventing type 2 diabetes and its
complications in Japan was more than USD 18.4 billion, which is a significant
cost to Japanese society,” said Bruno Angelici, Executive Vice President,
International Sales and Marketing Organisation, AstraZeneca. “We have a
long-standing presence in Japan, and our agreement with Bristol-Myers Squibb to
bring a potentially important type 2 diabetes treatment to market in the region
will not only help reduce this cost burden, but also reduce the impact this
disease has on the country's health.”

8 December 2008

- Ends -



Media: 	
Tracy Furey, Bristol-Myers Squibb, 609-252-3208, tracy.furey@bms.com
Jim Minnick, AstraZeneca, 302-866-5135, jim.minnick@astrazeneca.com

Investors:
John Elicker, Bristol-Myers Squibb, 212-546-3775, john.elicker@bms.com
Mina Blair, AstraZeneca, 44-20-7304-5084, mina.blair@astrazeneca.com	


About Dapagliflozin
Dapagliflozin was specifically designed to be a novel, selective inhibitor of
sodium glucose cotransporter 2 (SGLT2), which regulates the reabsorption of
glucose in the kidney. It has a C-glucoside chemical structure, which prolongs
the pharmacokinetic half-life and duration of action.  Dapagliflozin is
metabolized through the liver and excreted in the urine. Phase IIB data for
Dapagliflozin were presented at the 2008 American Diabetes Association Annual
Meeting and the 2008 European Association for the Study of Diabetes Annual
Meeting.     

About ONGLYZA™ (saxagliptin) 
In addition to the companies collaboration on dapagliflozin, Bristol-Myers
Squibb and AstraZeneca have been working together to develop another potential
treatment for type 2 diabetes -- ONGLYZA™ (saxagliptin) -- globally, excluding
Japan.  
ONGLYZA, the proposed tradename for saxagliptin, is an investigational DPP-4
inhibitor being studied in clinical trials as a once-daily therapy to determine
its efficacy and safety. Saxagliptin was specifically designed to be a selective
inhibitor with extended binding to the DPP-4 enzyme, with dual routes of
clearance. The companies submitted a New Drug Application to the U.S. Food &
Drug Administration (FDA) on June 30, which has been officially filed by the
FDA, and a Marketing Authorisation Application to the European Medicines Agency
(EMEA) on July 1, which has been accepted for review by the Agency.  The name
ONGLYZA, if approved by the FDA and the EMEA, will serve as the trade name for
saxagliptin.
Saxagliptin Phase III data have previously been presented as a monotherapy, as
well as in combination with metformin, sulfonylureas and thiazolidinediones,
commonly prescribed oral anti-diabetic medications. The overall clinical
development program included over 5,000 individuals -- more than 4,000 of whom
were given saxagliptin. The worldwide collaboration for the development and
commercialisation of saxagliptin will continue to exclude Japan.  On December
27, 2006, Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. announced an
exclusive licensing agreement for saxagliptin in Japan. 

About AstraZeneca
AstraZeneca is a major international healthcare business engaged in research,
development, manufacturing and marketing of prescription pharmaceuticals and
supplier for healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with healthcare sales of US $29.55 billion and is a
leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology
and infection product sales. AstraZeneca is listed in the Dow Jones
Sustainability Index (Global) as well as the FTSE4Good Index. For more
information visit www.astrazeneca.com

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to
extend and enhance human life. For more information, visit www.bms.com. 


# # #